

UTILITY
PATENT APPLICATION
TRANSMITTAL

Attorney Docket No. GA0182US

First Inventor or Application Identifier Landes, Gregory M

ISOLATION AND IDENTIFICATION OF SECRETED PROTEINS

Title

Express Mail Label No. EL 734 863 705 US

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 800 concerning design patent application contents.

- 1 ☒ Fee Transmittal Form (e.g., PTO/SB/17). **PTO/SB/17**
(Submit an original and a duplicate for fee processing.) **125 [0]**
- 2 ☐ Applicant claims small entity status.
See 37 CFR 1.27.
- 3 ☒ Specification [Total Pages **49**]
(preferred arrangement set forth below)
- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure
- 4 ☒ Drawing(s) (35 U.S.C.113) [Total Sheets **2**]
- 5 Oath or Declaration [Total Pages **3**]
a. ☒ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 CFR 1.63 (d))
(for a continuation/divisional with Box 17 completed)
☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b)
- 6 ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- 7 ☐ CD-ROM or CD-R in duplicate, large table or
Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
a. ☒ Computer Readable Form (CRF)
b. Specification Sequence Listing on:
i. ☐ CD-ROM or CD-R (2 copies); or
ii. ☒ paper 1 sheet
c. ☒ Statements verifying identity of above copies 2 sheets.

ACCOMPANYING APPLICATIONS PARTS

9. ☒ Assignment Papers (cover sheet & document(s)) **Copy**
10. ☐ 37 C.F.R. §3.73(b) Statement ☒ Power of
(when there is an assignee) Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
13. ☒ Preliminary Amendment 2 sheets
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,
or in an Application Data Sheet under 37 CFR 1.76-

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. _____/
Prior application information. Examiner _____ Group / Art Unit _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied
under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference.
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Labelor ☐ Correspondence address below

(Insert Customer No. or attach bar code label here)

Name	GENZYME CORPORATION					24536	
						PATENT/TRADEMARK OFFICE	
Address	15 PLEASANT STREET CONNECTOR						
	P.O. BOX 9322						
City	FRAMINGHAM	State	MA	Zip Code	01701-9322		
Country	USA	Telephone	508-872-8400		Fax	508-872-5415	

Name (Print/Type)	DEBORAH A. DUGAN	Registration No. (Attorney/Agent)	37,315
Signature		Date	02/01/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any
comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark
Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for
Patents, Box Patent Application, Washington, DC 20231

PTO
09/773841
02/01/01

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

\$1,232.00

Complete if Known

Application Number	Unassigned
Filing Date	01 February 2001
First Named Inventor	Landes, Gregory M.
Examiner Name	Unassigned
Group Art Unit	Unassigned
Attorney Docket No.	GA0182US

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to

Deposit Account Number **07-1074**

Deposit Account Name **GENZYME CORPORATION**

- ☒ Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17

☐ Applicant claims small entity status See 37 CFR § 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee Code		
(\$)	(\$)		
101 710 201 355	Utility filing fee		710.00
106 320 206 160	Design filing fee		
107 490 207 245	Plant filing fee		
108 710 208 355	Reissue filing fee		
114 150 214 75	Provisional filing fee		
SUBTOTAL (1)			\$710.00

2. EXTRA CLAIM FEES

	Extra Claims			Fee from below	Fee Paid
Total Claims	34	-20** =	14	X 18.00	= 252.00
Independent Claims	1	-3** =	0	X	= 0.00
Multiple Dependent				270.00	= 270.00

Large Entity Small Entity

Fee Code	Fee Code	Fee Description	
(\$)	(\$)		
103 150 203 9	Claims in excess of 20		
102 80 202 40	Independent claims in excess of 3		
04 270 204 135	Multiple dependent claim, if not paid		
109 80 209 40	** Reissue independent claims over original patent		
110 18 210 9	** Reissue claims in excess of 20 and over original patent		
SUBTOTAL (2)			\$522.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee Code		
(\$)	(\$)		
105 130 205 85	Surcharge - late filing fee or oath		
127 50 227 25	Surcharge - late provisional filing fee or cover sheet		
139 130 139 130	Non - English specification		
147 2,520 147 2,520	For filing a request for ex parte reexamination		
112 920* 112 920*	Requesting publication of SIR prior to Examiner action		
113 1,840* 113 1,840*	Requesting publication of SIR after Examiner action		
115 110 215 55	Extension for reply within first month		
116 390 216 195	Extension for reply within second month		
117 890 217 445	Extension for reply within third month		
118 1,390 218 695	Extension for reply within fourth month		
128 1,890 228 945	Extension for reply within fifth month		
119 310 219 155	Notice of Appeal		
120 310 220 155	Filing a brief in support of an appeal		
121 270 221 135	Request for oral hearing		
138 1,510 138 1,510	Petition to institute a public use proceeding		
140 110 240 55	Petition to revive - unavoidable		
141 1,240 241 620	Petition to revive - unintentional		
142 1,240 242 620	Utility issue fee (or reissue)		
143 440 243 220	Design issue fee		
144 600 244 300	Plant issue fee		
122 130 122 130	Petitions to the Commissioner		
123 50 123 50	Processing fee under 37 CFR § 1.17(q)		
126 180 126 180	Submission of Information Disclosure Statement		
581 40 581 40	Recording each patent assignment per property (times number of properties)		
146 710 246 355	Filing a submission after final rejection (37 CFR § 1.129(a))		
149 710 249 355	For each additional invention to be examined (37 CFR § 1.129(b))		
179 710 279 355	Request for Continued Examination (RCE)		
169 900 169 900	Request for expedited examination of a design application		
Other fee (specify)			
SUBTOTAL (3)			

*Reduced by Basic Filing Fee Paid

SUBMITTED BY

Name (Print/Type) **DEBORAH A. DUGAN**

Signature *Deborah A. Dugan*

Registration No.
(Attorney/Agent)

37,315

Complete if applicable

Telephone **508-270-2598**

Date **02/01/01**

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Landes, Gregory M.
APPLICATION NO: Unassigned GROUP NO: Unassigned
FILING DATE: February 1, 2001 EXAMINER: Unassigned
TITLE: ISOLATION AND IDENTIFICATION OF SECRETED PROTEINS

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that this paper or fee is being deposited on February 1, 2001 with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 as Express Mail Label No. EL 734 663 705 US and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231

February 1, 2001
Date

Taryn Antalek
Taryn Antalek

SUBMISSION OF PAPER COPY AND/OR COMPUTER READABLE COPY OF
SEQUENCE LISTING FOR INVENTION CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES


Pursuant to 37 C.F.R. §§ 1.821 – 1.824 Applicant submits herewith a paper copy and a computer readable copy of the Sequence Listing for the above-identified application.

Statement

I hereby state that (a) the content of the paper and computer readable copy submitted herewith are the same; (b) the content of the computer readable copy submitted herewith is the same as the Sequence Listing appearing on page 53 of the

original specification of U.S. Provisional Application Serial Number 60/180,582 as
filed on February 4, 2000; and (c) this submission includes no new matter.

Respectfully submitted,


Deborah A. Dugan
Registration No. 37,315

Genzyme Corporation
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322
Telephone: (508) 270-2598
Facsimile: (508) 872-5415